Reply to the letter to the editor ‘The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice’ by Hartmann and the letter ‘Comment on ESMO Magnitude of Clinical Benefit Scale’ by Muhonen et al.-Reference-Cited by-同舟云学术

Reply to the letter to the editor ‘The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice’ by Hartmann and the letter ‘Comment on ESMO Magnitude of Clinical Benefit Scale’ by Muhonen et al.

Published:2016-01 Issue:1 Volume:27 Page:205-207
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cherny N.I.,Sullivan R.,Dafni U.,Kerst J.M.,Sobrero A.,Zielinski C.,de Vries E.G.E.,Piccart M.J.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/1/203/6677532/mdv502.pdf

Reference6 articles.

1. Comment on ESMO Magnitude of Clinical Benefit Scale;Muhonen;Ann Oncol,2015

2. The ESMO magnitude of clinical benefit scaling tool: from theory to practice;Hartmann;Ann Oncol,2015

3. European network for Health Technology Assessment. Guideline: Endpoints used for relative effectiveness assessment of pharmaceuticals: Clinical endpoints In. 2013; http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Clinical%20endpoints.pdf (28 October 2015, date last accessed).

4. European network for Health Technology Assessment. Guideline: Endpoints used in relative effectiveness assessment of pharmaceuticals: Surrogate Endpoints In. 2013; http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Surrogate%20Endpoints.pdf (28 October 2015, date last accessed).

5. European network for Health Technology Assessment. Guideline: Levels of evidence: Applicability of evidence in the context of a relative effectiveness assessment of pharmaceuticals: health-related quality of life and utility measures In. 2013; http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Health-related%20quality%20of%20life.pdf (28 October 2015, date last accessed).

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Five years of EMA-approved systemic cancer therapies for solid tumours—a comparison of two thresholds for meaningful clinical benefit;European Journal of Cancer;2017-09

2. Industry corner: perspectives and controversies - The challenges of patient access to new medicines;Annals of Oncology;2017-03

3. Utilisation of the ESMO-MCBS in practice of HTA;Annals of Oncology;2016-11